Breaking News from Biotop:
Recently, the Jiangsu Provincial Department of Industry and Information Technology announced the list of provincial specialized, refined, unique, and innovative small and medium-sized enterprises for 2025 (second batch).List, Abogen Biosciences, incubated by BioBAY、HSGDSelected,Take a look with Baituo Jun~
"Specialized, Precise, Unique, and Innovative" small and medium-sized enterprises (SMEs) refer to SMEs that possess the characteristics of specialization, precision, uniqueness, and innovation, and are advanced and exemplary enterprises in niche industries.
? ? ?
Selected Enterprises
(The order is not ranked) |
| Abogen Biosciences |
|
| HSGD (Suzhou) Biomedical Technology Co., Ltd. |
Click on the link at the end of the article to read the full list.Abogen BiosciencesTechnology Co., Ltd.
Abogen Biosciences moved into the BioTOP co-working space in March 2019 and was incubated to BioBAY for further development in June 2020. As an innovative biopharmaceutical company specializing in the research and development of messenger ribonucleic acid (mRNA) drugs, Abogen possesses a leading, proprietary technology platform in the industry for mRNA and nanodelivery systems. It is one of the few mRNA drug R&D enterprises in China with complete value chain capabilities, covering all aspects from mRNA design, formulation development, to large-scale production. The company has established a rich pipeline of products spanning multiple fields, including cancer immunotherapy, autoimmune diseases, and infectious disease prevention.
HSGD (Suzhou) Biomedical Technology Co., Ltd.
HSGD moved into BioTOP in September 2020 and graduated to BioBAY in September 2021 to continue its development.It has now grown into one of the leading companies in China in the minimally invasive glaucoma sector. Among its products, the "Trabecular Meshwork Ultra-Micro Stent Drainage System" is designed for patients with open-angle glaucoma and is one of the smallest Class III implants globally. In February 2024, this product entered the National Medical Device Innovation Fast Track, breaking foreign technological monopolies and filling the gap in this field in China.
Congratulations to the above two companies for being successfully selected! BioTop Maker Space will always stay true to its original mission, focusing on incubating early-stage innovation projects in the life sciences field. It will fully integrate advantageous resources from the biopharmaceuticals industry to provide high-quality services and an efficient information exchange platform for入驻企业提供优质的服务和高效的信息互动交流平台，助力企业高速发展！Source: BioBAY, Abogen, HSGDBioVenture丨SinoBiologics Completes Over $1.1 Billion Series B Financing
Training Registration | December 16-17, Advanced Training for Management Representatives of Medical Device Manufacturing Enterprises, Now Open for Enrollment
X-BioTOP, the early innovation frontier incubator of BioBAY. Operated and managed by BioTOP, it is dedicated to incubation services for early-stage innovative entrepreneurial companies in the global biopharmaceutical field. In 2020, X-BioTOP successfully registered as a "National Maker Space."From March 2017 to present, X-BioTOP has signed a cumulative total of 206 projects. It has currently established five service packages, including shared administrative services, entrepreneurship training, resource activities, business development, and technical services. A total of 47 enterprises have received financing amounting to 19.139 billion RMB, and 76 projects have received support from talent policies at various levels.Swipe left and right to view the company environment
